Health status following an acute exacerbation of chronic bronchitis (AECB) is better in patients receiving gemifloxacin compared with clarithromycin Source: Eur Respir J 2001; 18: Suppl. 33, 542s Year: 2001
Pharmacodynamics of levofloxicin in patients with acute exacerbation of chronic bronchitis Source: Eur Respir J 2002; 20: Suppl. 38, 546s Year: 2002
Comparison of the efficacy of azythromycin and roxithromycin in the treatment of acute purulent exacerbation of chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: Suppl. 33, 138s Year: 2001
Five-day telithromycin is as effective as 10-day clarithromycin in the treatment of acute exacerbations of chronic bronchitis Source: Eur Respir J 2003; 22: Suppl. 45, 351s Year: 2003
Efficacy and safety of various antimicrobial regimens in the treatment of acute exacerbations of chronic bronchitis Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007
Efficacy of azithromycin vs. ciprofloxacin in the treatment of patients with acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 544s Year: 2002
Efficacy of levofloxacin (LVF) in the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with risk factors Source: Annual Congress 2003 - Acute exacerbations of asthma and COPD Year: 2003
Comparative evaluation of fluoroquinolone efficiency in treatment of infectious acute attack of chronic obstructive bronchitis Source: Eur Respir J 2004; 24: Suppl. 48, 512s Year: 2004
Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with acute exacerbations of chronic bronchitis (AECB) in PROTEKT years 1–5 (1999–2004) Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients Year: 2006
Clinical features of chronic pulmonary aspergillosis treated with voriconazole in patients with chronic respiratory disease Source: Annual Congress 2008 - Biomarkers and antibiotic treatment of exacerbations of COPD Year: 2008
Efficacy and safety of moxifloxacin in the outpatient treatment of exacerbations of chronic obstructive pulmonary disease Source: International Congress 2018 – Pharmacological management of COPD Year: 2018
5-day moxifloxacin versus 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis: a cost-minimization analysis Source: Eur Respir J 2003; 22: Suppl. 45, 336s Year: 2003
Antibiotic prescribing in patients with acute bronchitis Source: Annual Congress 2007 - Primary care respiratory problems Year: 2007
Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results Source: Eur Respir J 2012; 40: 17-27 Year: 2012
Penetration of moxifloxacin in bronchial secretions in hospitalized patients with acute exacerbation of COPD Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013
Antibacterial activity of telithromycin (TEL) and comparators against bacterial pathogens isolated from patients with acute exacerbations of chronic bronchitis (AECB) in the PROTEKT study 1999–2002 Source: Eur Respir J 2004; 24: Suppl. 48, 641s Year: 2004
Microorganisms resistant to conventional antimicrobial treatment in acute exacerbation of COPD Source: International Congress 2017 – Respiratory infections in critically ill and immuno-depressed patientes Year: 2017
Placebo-controlled, double-blind trial of chronic, intermittent ‘pulse‘ therapy of moxifloxacin to prevent acute exacerbations in COPD patients with chronic bronchitis: baseline data Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients Year: 2006
The efficacy and treatment length of oral corticosteroids in patient with acute exacerbation of chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 295s Year: 2005